Single Domain Biotherapeutics

Single Domain Biotherapeutics

Optimising next generation T-cell re-directing immunotherapy

A role for VHH single
domain antibodies

Welcome to

Isogenica

Excellence in Single Domain Biotherapeutics

Isogenica develops LlamdA® VHH: highly versatile small format antibodies which we use to construct next generation biotherapeutics for the treatment of cancer, inflammation and other serious diseases.

LlamdA® VHH can be assembled to create bispecific and multi-specific biotherapeutics, or used to achieve targeted drug delivery as components of ADCs and cell and gene therapies including CAR-Ts.

Isogenica’s partnerships with global biopharmaceutical companies have resulted in a deep pipeline including one clinical Phase II asset and eleven partnered pre-clinical and discovery programs.

Isogenica works with partners through collaborative research and commercial licenses to further develop proprietary LlamdA® VHH or to discover novel LlamdA® VHH as direct therapeutics and targeting agents.

Partnerships

Isogenica Biopharmaceutical Partnerships

Accelerated Discovery

Isogenica’s LlamdA® VHH synthetic libraries are displayed in phage or in the company’s proprietary CIS Display technology.

These are combined to provide a powerful discovery engine for single domain biotherapeutics.

News & Events

Careers at Isogenica

A career at Isogenica provides an opportunity to lead, execute or support the commercial development of next generation biotherapeutics.